This interview with a UK-based key opinion leader (KOL) offers comprehensive insights into current disease landscape for spinal muscular atrophy (SMA) patients, and expectations regarding emerging pipeline therapies. The discussion covers the current treatment paradigm, as well as perspectives on the myostatin-targeted class and its prospective roles in future disease management. Key assets highlighted include Evrysdi, Spinraza, Zolgensma, apitegromab, taldefgrobep alfa, and GYM329.

This interview was conducted on 13 October 2025.